[HTML][HTML] Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma
M Barone, MT Viggiani, G Losurdo… - World Journal of …, 2019 - ncbi.nlm.nih.gov
M Barone, MT Viggiani, G Losurdo, M Principi, A Di Leo
World Journal of gastroenterology, 2019•ncbi.nlm.nih.govBACKGROUND Neoangiogenesis is one of the key pathogenetic mechanisms in
hepatocellular carcinoma (HCC). Modulation of the renin-angiotensin system (RAS) by
angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers
(ARBs) seems to be a possible adjuvant therapy for HCC, due to the anti-angiogenic and
anti-fibrogenic activity of these drugs. AIM
hepatocellular carcinoma (HCC). Modulation of the renin-angiotensin system (RAS) by
angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers
(ARBs) seems to be a possible adjuvant therapy for HCC, due to the anti-angiogenic and
anti-fibrogenic activity of these drugs. AIM
Abstract
BACKGROUND
Neoangiogenesis is one of the key pathogenetic mechanisms in hepatocellular carcinoma (HCC). Modulation of the renin-angiotensin system (RAS) by angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) seems to be a possible adjuvant therapy for HCC, due to the anti-angiogenic and anti-fibrogenic activity of these drugs.
AIM
ncbi.nlm.nih.gov